[HTML][HTML] Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study
Introduction This study characterizes patients receiving evolocumab in clinical practice and
assesses treatment effectiveness, safety and persistence outcomes across five countries …
assesses treatment effectiveness, safety and persistence outcomes across five countries …
[HTML][HTML] Real-world insights into evolocumab use in patients with hyperlipidemia: Canadian analysis from the ZERBINI study
Abstract Background The 2021 Canadian Cardiovascular Society guidelines recommend
proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with …
proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with …
[HTML][HTML] Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study
C Ebenbichler, H Drexel, U Hanusch, H Toplak… - Wiener klinische …, 2024 - Springer
Background This real-world study examined clinical characteristics and dyslipidemia
management among patients initiating evolocumab across 12 European countries. Austrian …
management among patients initiating evolocumab across 12 European countries. Austrian …
Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study
KK Ray, E Bruckert, B Van Hout… - European Heart …, 2020 - academic.oup.com
Background 2019 ESC/EAS dyslipidaemia guidelines recommend a 50% lowering in
untreated LDL-C and use of PCSK9 inhibitors (PCSK9i) for patients at very-high …
untreated LDL-C and use of PCSK9 inhibitors (PCSK9i) for patients at very-high …
Evolocumab is initiated in Central and Eastern Europe at much higher LDL-C levels than recommended in guidelines: Results from the observational HEYMANS study
V Blaha, R Margoczy, I Petrov… - Journal of …, 2023 - journals.sagepub.com
Purpose: We examined clinical characteristics and low-density lipoprotein cholesterol (LDL-
C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern …
C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern …
[HTML][HTML] Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results …
K Al Faraidy, M Akbar, M Shehri, M Aljarallah… - PLoS …, 2023 - journals.plos.org
Objectives Dyslipidemia is a prevalent condition with significant morbidity and mortality
across the world, including in the Arabian Gulf. The present study aimed to describe the …
across the world, including in the Arabian Gulf. The present study aimed to describe the …
Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study
I Sudano, S Krähenbühl, F Mach… - Therapeutic …, 2024 - journals.sagepub.com
Aims: The HEYMANS study observed patients receiving evolocumab as part of routine
clinical hyperlipidemia management. It was designed to capture data on clinical parameters …
clinical hyperlipidemia management. It was designed to capture data on clinical parameters …
First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study
Objective To present the first registry used to analyse the clinical profile of patients treated
with evolocumab in Spain, including the effectiveness on the lipid profile and safety in the …
with evolocumab in Spain, including the effectiveness on the lipid profile and safety in the …
Real-world clinical profile of patients prescribed evolocumab in Japan
F Sheng, AY Wang, K Miyawaki, T Tsuchiya… - Circulation …, 2024 - jstage.jst.go.jp
Background: Real-world utilization data for evolocumab, the first proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitor to be introduced in Japan in 2016, to date are …
subtilisin/kexin type 9 (PCSK9) inhibitor to be introduced in Japan in 2016, to date are …
Evolocumab and clinical outcomes in patients with cardiovascular disease
MS Sabatine, RP Giugliano, AC Keech… - New England journal …, 2017 - Mass Medical Soc
Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …